Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluperolone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Fluperolone is a synthetic fluorinated prednisolone derivative classified as a corticosteroid. It is primarily used topically for its anti-inflammatory activity in the treatment of various dermatoses. As a member of the 20-oxosteroids class, it acts as an agonist of the glucocorticoid receptor, modulating gene expression to suppress inflammation and immune responses. Fluperolone is considered moderately potent among topical corticosteroids and has been marketed under names such as Methral.
- Brand names
- Methral
- Other names
- fluperolone acetate
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on fluperolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluperolone.